跳转至内容
Merck
CN

B1401

缓激肽片段 1-5

≥97% (HPLC)

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C27H40N8O6
化学文摘社编号:
分子量:
572.66
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

缓激肽片段 1-5, ≥97% (HPLC)

InChI

1S/C27H40N8O6/c28-18(9-4-12-31-27(29)30)24(38)35-14-6-11-21(35)25(39)34-13-5-10-20(34)23(37)32-16-22(36)33-19(26(40)41)15-17-7-2-1-3-8-17/h1-3,7-8,18-21H,4-6,9-16,28H2,(H,32,37)(H,33,36)(H,40,41)(H4,29,30,31)

SMILES string

NC(CCCNC(N)=N)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NCC(=O)NC(Cc3ccccc3)C(O)=O

InChI key

USSUMSBPLJWFSZ-UHFFFAOYSA-N

assay

≥97% (HPLC)

form

powder

UniProt accession no.

storage temp.

−20°C

Quality Level

Gene Information

Biochem/physiol Actions

缓激肽(BK)片段(1-5)(RPPGF)是最稳定的天然代谢产物之一。可作为体内缓激肽产生的标志物。其生物活性依赖于C末端的一个完整的精氨酸(Arg)残基。BK 1-5是抑制α-凝血酶诱导的血小板聚集和分泌及钙离子动员的必需肽。还可抑制α-凝血酶在精氨酸和丝氨酸之间的位点切割凝血酶受体肽NATLDPRSFLLR。BK 1-5的这种抗凝血酶活性可能与激肽的心脏保护作用有关。

Packaging

无底玻璃瓶。内含物装在锥底内插管中。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

常规特殊物品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Elizabeth A Girnys et al.
Bioorganic & medicinal chemistry, 19(24), 7425-7434 (2011-11-08)
The serine protease thrombin plays several key roles in the clotting cascade within the hemostatic system, such as in fibrin formation and platelet activation. Thus, development of an inhibitor that binds to the enzyme's active site (a direct thrombin inhibitor)
Marvin T Nieman et al.
FEBS letters, 579(1), 25-29 (2004-12-29)
The angiotensin converting enzyme breakdown product of bradykinin, bradykinin 1-5 (RPPGF), inhibits thrombin-induced human or mouse platelet aggregation. RPPGF binds to the exodomain of human protease-activated receptor 1 (PAR1). Studies determined if RPPGF also binds to the exodomain of human
Mias Pretorius et al.
Arteriosclerosis, thrombosis, and vascular biology, 25(11), 2435-2440 (2005-09-17)
Angiotensin-converting enzyme inhibition (ACEI) increases vascular tissue plasminogen activator (t-PA) release through endogenous bradykinin (BK). We tested the hypothesis that gender influences the effect of ACEI on t-PA release. We measured the effect of intra-arterial enalaprilat (0.33 microg/min per 100
M T Nieman et al.
Journal of thrombosis and haemostasis : JTH, 6(5), 837-845 (2008-03-05)
Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF. These peptides are direct thrombin inhibitors prolonging the thrombin clotting time
L J Murphey et al.
Circulation, 102(8), 829-832 (2000-08-23)
Bradykinin is a cardioprotective peptide metabolized by the angiotensin-converting enzyme (ACE). An insertion/deletion (I/D) polymorphism in the ACE gene determines plasma ACE levels. The D allele is associated with cardiovascular disease, which may relate to enhanced angiotensin II production or

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持